Dexamethasone–Decanoic Acid Compositions to Reduce Cartilage Loss

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current pharmaceutical interventions for osteoarthritis, such as corticosteroids, cause severe side effects like cartilage loss and bone fractures, and there is a need for safe and effective treatments to manage inflammation and prevent progressive disability.

Innovation Solution

Pharmaceutical compositions combining medium-chain fatty acids, carboxylates, and monoglycerides with corticosteroids, such as dexamethasone, display synergistic anti-inflammatory properties, reducing the required corticosteroid dose and minimizing side effects while promoting chondrocyte re-differentiation and collagen production.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If corticosteroids are used to treat osteoarthritis inflammation, then anti-inflammatory effect is improved, but cartilage loss and bone fractures occur

Engineering Contradiction:

Improveanti-inflammatory effectVSAvoidcartilage loss and bone fractures

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent combines medium-chain fatty acids (such as decanoic acid) with corticosteroids (such as dexamethasone) to create a composite pharmaceutical composition. This combination allows the fatty acid to enhance the anti-inflammatory effect while reducing the harmful side effects on cartilage and bone, thereby resolving the contradiction between therapeutic efficacy and safety

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The patent changes the chemical composition parameters by introducing medium-chain fatty acids with specific chain lengths (6-12 carbons) into the pharmaceutical formulation. This parameter change enables synergistic anti-inflammatory action while minimizing cartilage toxicity, thus improving reliability without worsening harmful effects

Inventive Principle:

Principle #35Parameter changes

2Reliability

If high doses of corticosteroids are administered, then inflammation is reduced, but side effects increase

Engineering Contradiction:

Improveinflammation reductionVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent merges medium-chain fatty acids with corticosteroids in a single pharmaceutical composition. The fatty acid component synergistically enhances the anti-inflammatory action of the corticosteroid, allowing for reduced corticosteroid dosing while maintaining or improving inflammation control, thereby reducing side effects

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The medium-chain fatty acid acts as an intermediary substance that modulates the interaction between the corticosteroid and inflammatory pathways. It enhances the therapeutic effect of the corticosteroid while protecting against its harmful side effects, thus enabling effective inflammation reduction with minimized adverse effects

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20250288599A1Pharmaceutical compositions and methods for treating osteoarthritis

Publication Date: 2025.09.18 INSIGNIA PHARM LLC

AI summary

A pharmaceutical composition is provided. The pharmaceutical composition includes dexamethasone at a concentration of at least 400 picomolar and up to 20 millimolar and decanoic acid at a concentration of at least 10 micromolar and up to 5 millimolar. In some embodiments, the pharmaceutical composition is used to treat osteoarthritis.